We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Core Target and Key Signal Pathway of Xiaoluo in the Treatment of Thyroid Cancer.
- Authors
Wei Liang; Kun Zhang; Yu Sun; Lixin Chen; Zishuo Wang; Wei Cheng; Wenlan Li
- Abstract
Context • At present, hormone therapy and surgery are the main treatments for thyroid cancer, and they have a quick effect but a high recurrence rate. Also, the side effects are significant. it’s extremely urgent to explore treatments that can take into account both therapeutic benefits and side effects. Objective • The study intended to explore whether Xiaoluo has an inhibitory effect on the proliferation of thyroid-cancer cells in vitro and to examine the core target and key signaling pathway of Xiaoluo in the treatment of thyroid cancer, using the thyroid-cancer cell line SW579. Design • The research team performed an in-vitro study. Setting • The study took place at the College of Pharmacy at Harbin University of Commerce in Harbin, China. Outcome Measures • The research team used a Western blot analysis to detect the expression of apoptosis proteins—B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and Caspase-3—and the activity related to the signaling pathways phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin 1 (mTORC1). The team measured optical densities and inhibition rates for the 1, 2, 5, 10, and 15 mg/mL Xiaokuo groups and for a negative control group. The research team measured apoptosis, expression of Bcl-2, Bax, and Caspase-3, and expression of P13K, AKT, and mTor for the 10 μmol/L LY294002, 10 mg/mL Xiaoluo, 100 ng/mL IGF-1, and 100 ng/mL IGF-1+10 mg/mL Xiaoluo groups and for the blank control group. Results • The inhibition of SW579 cell proliferation increased with each increase in the Xiaoluo concentration from 1-15 mg/mL, and the inhibition rate reached 49.63% when the concentration was 15 mg/ml. The Xiaoluo group’s late and total apoptosis rates were significantly higher (both P<.01) than those of the blank control group. The Xiaoluo group’s expression of the Bcl-2 protein was significantly lower (P < .05), and its expressions of Bax and Caspase-3 were significantly higher (both P<.01) than those of the blank control group. The Xiaoluo group’s expressions of P-PI3K, P-Akt, and P-MTOR were significantly lower than those of the blank group (all P < .01). These findings were comparable to those that occurred with use of the PI3K/ AKT/mTORC1 signaling pathway inhibitor LY294002. Conclusions • Xiaoluo exerts its antithyroid-cancer effects through the induction of apoptosis in thyroid cancer cells through the inhibition of the PI3K/AKT/mTORC1 signaling pathway. Xiaoluo may serve as a potential therapeutic agent for the treatment of thyroid cancer.
- Subjects
THYROID cancer; HORMONE therapy; RAPAMYCIN; PHOSPHOINOSITIDES; GENE expression
- Publication
Alternative Therapies in Health & Medicine, 2023, Vol 29, Issue 5, p400
- ISSN
1078-6791
- Publication type
Article